Advertisement

C-reactive protein velocity and the risk of acute kidney injury among ST elevation myocardial infarction patients undergoing primary percutaneous intervention

  • David Zahler
  • Keren-Lee Rozenfeld
  • Maya Stein
  • Assi Milwidsky
  • Shlomo Berliner
  • Shmuel Banai
  • Yaron Arbel
  • Yacov ShachamEmail author
Original Article
  • 18 Downloads

Abstract

Background

Elevated C-reactive protein (CRP) was shown to be associated with an increased risk for acute kidney injury (AKI) in ST elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI), however, the optimal time frame to measure CRP for risk stratification is not known. We evaluated the relation between the change in CRP over time (CRP velocity-CRPv) and AKI among STEMI patients treated with primary PCI.

Methods

We included 801 STEMI who presented between 2007 and 2017 and had their CRP measured with a wide range assay (wr-CRP) at least twice during the 24 h after admission. CRPv was defined as the change in wr-CRP concentration (mg/l) divided by the change in time (in h) between the two measurements. Patient’s medical records were reviewed for occurrence of AKI.

Results

Mean age was 62 ± 16 and 80% were males. Patients with AKI had significantly higher CRPv (1.47 versus 0.4 mg/l/h, p < 0.001). In a multivariate regression model CRPv was independently associated with AKI (OR 1.03, 95% CI 1.01–1.0 5, p = 0.001). On receiver operating characteristic (ROC) curve the optimal cutoff value of CRPv to predict AKI was measured as more than 0.8 mg/l/h, with 70% sensitivity and 65% specificity (AUC 0.712, 95% CI 0.64–0.78, p < 0.001).

Conclusion

CRPv might be an independent and rapidly measurable biomarker for AKI following primary PCI in STEMI patients.

Keywords

C-reactive protein Acute kidney injury Acute myocardial infarction Biomarkers 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The study protocol was approved by the local institutional ethics committee.

References

  1. 1.
    Bursi F, Weston SA, Killian JM, Gabriel SE, Jacobsen SJ, Roger VL (2007) C-reactive protein and heart failure after myocardial infarction in the community. Am J Med 120(7):616–622.  https://doi.org/10.1016/j.amjmed.2006.07.039 CrossRefGoogle Scholar
  2. 2.
    Suleiman M, Khatib R, Agmon Y, Mahamid R, Boulos M, Kapeliovich M, Levy Y, Beyar R, Markiewicz W, Hammerman H, Aronson D (2006) Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C-reactive protein. J Am Coll Cardiol 47(5):962–968.  https://doi.org/10.1016/j.jacc.2005.10.055 CrossRefGoogle Scholar
  3. 3.
    Shacham Y, Leshem-Rubinow E, Ben Assa E, Rogowski O, Topilsky Y, Roth A, Steinvil A (2013) Comparison of C-reactive protein and fibrinogen levels in patients having anterior wall ST-Segment elevation myocardial infarction with versus without left ventricular thrombus (from a primary percutaneous coronary intervention cohort). Am J Cardiol 112(1):57–60.  https://doi.org/10.1016/j.amjcard.2013.02.052 CrossRefGoogle Scholar
  4. 4.
    Margolis G, Gal-Oz A, Letourneau-Shesaf S, Khoury S, Keren G, Shacham Y (2018) Acute kidney injury based on the KDIGO criteria among ST elevation myocardial infarction patients treated by primary percutaneous intervention. J Nephrol 31(3):428–428.  https://doi.org/10.1007/s40620-017-0461-3 CrossRefGoogle Scholar
  5. 5.
    Fertin M, Hennache B, Hamon M, Ennezat PV, Biausque F, Elkohen M, Nugue O, Tricot O, Lamblin N, Pinet F, Bauters C (2010) Usefulness of serial assessment of B-type natriuretic peptide, troponin I, and C-reactive protein to predict left ventricular remodeling after acute myocardial infarction (from the REVE-2 study). Am J Cardiol 106(10):1410–1416.  https://doi.org/10.1016/j.amjcard.2010.06.071 CrossRefGoogle Scholar
  6. 6.
    Orn S, Manhenke C, Ueland T, Damas JK, Mollnes TE, Edvardsen T, Aukrust P, Dickstein K (2009) C-reactive protein, infarct size, microvascular obstruction, and left-ventricular remodelling following acute myocardial infarction. Eur Heart J 30(10):1180–1186.  https://doi.org/10.1093/eurheartj/ehp070 CrossRefGoogle Scholar
  7. 7.
    Gao F, Zhou YJ, Zhu X, Wang ZJ, Yang SW, Shen H (2011) C-reactive protein and the risk of contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention. Am J Nephrol 34(3):203–210.  https://doi.org/10.1159/000329534 CrossRefGoogle Scholar
  8. 8.
    Shacham Y, Leshem-Rubinow E, Steinvil A, Keren G, Roth A, Arbel Y (2015) High sensitive C-reactive protein and the risk of acute kidney injury among ST elevation myocardial infarction patients undergoing primary percutaneous intervention. Clin Exp Nephrol 19(5):838–843.  https://doi.org/10.1007/s10157-014-1071-1 CrossRefGoogle Scholar
  9. 9.
    Dimitrijevic O, Stojcevski BD, Ignjatovic S, Singh NM (2006) Serial measurements of C-reactive protein after acute myocardial infarction in predicting one-year outcome. Int Heart J 47(6):833–842CrossRefGoogle Scholar
  10. 10.
    Dominguez-Rodriguez A, Abreu-Gonzalez P, Avanzas P (2013) Prognostic usefulness of C-reactive protein: importance of the diurnal variation. Am J Cardiol 111(7):1079–1080.  https://doi.org/10.1016/j.amjcard.2013.01.283 CrossRefGoogle Scholar
  11. 11.
    Kosuge M, Ebina T, Hibi K, Ishikawa T, Endo M, Mitsuhashi T, Hashiba K, Umemura S, Kimura K (2008) Value of serial C-reactive protein measurements in non ST-segment elevation acute coronary syndromes. Clin Cardiol 31(9):437–442.  https://doi.org/10.1002/clc.20267 CrossRefGoogle Scholar
  12. 12.
    American College of Emergency Society for Cardiovascular P, Interventions A, O’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX, Anderson JL, Jacobs AK, Halperin JL, Albert NM, Brindis RG, Creager MA, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Kushner FG, Ohman EM, Stevenson WG, Yancy CW (2013) 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 61 (4):e78–e140.  https://doi.org/10.1016/j.jacc.2012.11.019 CrossRefGoogle Scholar
  13. 13.
    Arbel Y, Eros Y, Rogowski O, Berliner S, Shapira I, Keren G, Vered Y, Banai S (2007) Comparison of values of wide-range C-reactive protein to high-sensitivity C-reactive protein in patients undergoing coronary angiography. Am J Cardio 99(11):1504–1506.  https://doi.org/10.1016/j.amjcard.2007.01.020 CrossRefGoogle Scholar
  14. 14.
    Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, Ckd EPI (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604–612CrossRefGoogle Scholar
  15. 15.
    Kellum JA, Lameire N, Group KAGW (2013) Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care 17(1):204.  https://doi.org/10.1186/cc11454 CrossRefGoogle Scholar
  16. 16.
    Vrsalovic M, Pintaric H, Babic Z, Pavlov M, Vrsalovic Presecki A, Getaldic B, Vrkic N, Nikolic Heitzler V (2012) Impact of admission anemia, C-reactive protein and mean platelet volume on short term mortality in patients with acute ST-elevation myocardial infarction treated with primary angioplasty. Clin Biochem 45(16–17):1506–1509.  https://doi.org/10.1016/j.clinbiochem.2012.05.026 CrossRefGoogle Scholar
  17. 17.
    Registry MKMI, Meisinger C, Heier M, von Scheidt W, Kuch B (2010) Admission C-reactive protein and short-as well as long-term mortality in diabetic versus non-diabetic patients with incident myocardial infarction. Clin Res Cardiol 99(12):817–823.  https://doi.org/10.1007/s00392-010-0193-z CrossRefGoogle Scholar
  18. 18.
    Kuch B, von Scheidt W, Kling B, Heier M, Hoermann A, Meisinger C (2008) Differential impact of admission C-reactive protein levels on 28-day mortality risk in patients with ST-elevation versus non-ST-elevation myocardial infarction (from the Monitoring Trends and Determinants on Cardiovascular Diseases [MONICA]/Cooperative Health Research in the Region of Augsburg [KORA] Augsburg Myocardial Infarction Registry). Am J Cardiol 102(9):1125–1130.  https://doi.org/10.1016/j.amjcard.2008.06.034 CrossRefGoogle Scholar
  19. 19.
    Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM (1993) C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 82(2):513–520Google Scholar
  20. 20.
    Fujii H, Li SH, Szmitko PE, Fedak PW, Verma S (2006) C-reactive protein alters antioxidant defenses and promotes apoptosis in endothelial progenitor cells. Arterioscler Thromb Vasc Biol 26(11):2476–2482.  https://doi.org/10.1161/01.ATV.0000242794.65541.02 CrossRefGoogle Scholar
  21. 21.
    Russo D, Minutolo R, Cianciaruso B, Memoli B, Conte G, De Nicola L (1995) Early effects of contrast media on renal hemodynamics and tubular function in chronic renal failure. J Am Soc Nephrol 6(5):1451–1458Google Scholar
  22. 22.
    Milwidsky A, Ziv-Baran T, Letourneau-Shesaf S, Keren G, Taieb P, Berliner S, Shacham Y (2017) CRP velocity and short-term mortality in ST segment elevation myocardial infarction. Biomarkers 22(3–4):383–386.  https://doi.org/10.1080/1354750X.2017.1279218 CrossRefGoogle Scholar
  23. 23.
    Xinwei J, Xianghua F, Jing Z, Xinshun G, Ling X, Weize F, Guozhen H, Yunfa J, Weili W, Shiqiang L (2009) Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol 104(4):519–524.  https://doi.org/10.1016/j.amjcard.2009.04.014 CrossRefGoogle Scholar
  24. 24.
    Mager A, Vaknin Assa H, Lev EI, Bental T, Assali A, Kornowski R (2011) The ratio of contrast volume to glomerular filtration rate predicts outcomes after percutaneous coronary intervention for ST-segment elevation acute myocardial infarction. Catheter Cardiovasc Interv 78:198–201CrossRefGoogle Scholar
  25. 25.
    Marenzi G, De Metrio M, Rubino M, Lauri G, Cavallero A, Assanelli E, Grazi M, Moltrasio M, Marana I, Campodonico J, Discacciati A, Veglia F, Bartorelli AL (2010) Acute hyperglycemia and contrast-induced nephropathy in primary percutaneous coronary intervention. Am Heart J 160:1170–1177CrossRefGoogle Scholar
  26. 26.
    Kanic V, Vollrath M, Kompara G, Suran D, Hojs R (2018) Woman and acute kidney injury in myocardial infarction. J Nephrol 31(5):713–719.  https://doi.org/10.1007/s40620-018-0504-4 CrossRefGoogle Scholar
  27. 27.
    Sorensen-Zender I, Rong S, Susnik N, Lange J, Gueler F, Degen JL, Melk A, Haller H, Schmitt R (2013) Role of fibrinogen in acute ischemic kidney injury. Am J Physiol Renal Physiol 305(5):F777–F785.  https://doi.org/10.1152/ajprenal.00418.2012 CrossRefGoogle Scholar
  28. 28.
    Coca SG, Yalavarthy R, Concato J, Parikh CR (2008) Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review. Kidney Int 73(9):1008–1016.  https://doi.org/10.1038/sj.ki.5002729 CrossRefGoogle Scholar
  29. 29.
    Koyner JL, Parikh CR (2013) Clinical utility of biomarkers of AKI in cardiac surgery and critical illness. Clin J Am Soc Nephrol 8(6):1034–1042.  https://doi.org/10.2215/CJN.05150512 CrossRefGoogle Scholar

Copyright information

© Italian Society of Nephrology 2019

Authors and Affiliations

  1. 1.Department of Cardiology, Tel-Aviv Sourasky Medical Center, Sackler Faculty of MedicineTel-Aviv UniversityTel AvivIsrael

Personalised recommendations